Banner
Opioid Addicts Are Less Likely To Use Legal Opioids At The End Of Their Lives

With a porous southern border, street fentanyl continues to enter the United States and be purchased...

More Like Lizards: Claim That T. Rex Was As Smart As Monkeys Refuted

A year ago, corporate media promoted the provocative claim that dinosaurs like Tyrannorsaurus rex...

Study: Caloric Restriction In Humans And Aging

In mice, caloric restriction has been found to increase aging but obviously mice are not little...

Science Podcast Or Perish?

When we created the Science 2.0 movement, it quickly caught cultural fire. Blogging became the...

User picture.
News StaffRSS Feed of this column.

News Releases From All Over The World, Right To You... Read More »

Blogroll

A University of Utah study shows how various regions of North America are kept afloat by heat within Earth’s rocky crust, and how much of the continent would sink beneath sea level if not for heat that makes rock buoyant.

Of coastal cities, New York City would sit 1,427 feet under the Atlantic, Boston would be 1,823 feet deep, Miami would reside 2,410 feet undersea, New Orleans would be 2,416 underwater and Los Angeles would rest 3,756 feet beneath the Pacific.

Fibromyalgia is a chronic, widespread pain in muscles and soft tissues accompanied by fatigue that does not manifest any structural damage in an organ.

It affects approximately 2% of the US population, is an example of a class of maladies called CSS. These diseases are based on neurochemical abnormalities and include irritable bowel syndrome, migraine and restless legs syndrome.

Twenty-five years ago, Muhammad B. Yunus, MD, and colleagues published the first controlled study of the clinical characteristics of fibromyalgia syndrome.

Now Yunus and his team have done a critical review of over 225 publications and the author’s broad experience in fibromyalgia and related diseases.

We all have tastes we love, and tastes we hate. And yet, our "taste" for certain flavors and foods can change over time, as we get older or we get tired of eating the same old thing.

A University of Michigan study gives evidence about what's going on in the brain when we taste something we like, or develop a liking for something we once hated.

And although the study used rats instead of people, it has direct implications for understanding the way we perceive pleasure – and the reasons why some people develop problems, such as drug abuse, depression or anorexia, that knock their pleasure response off balance.

Pediatricians now have a practical tool to help determine whether children with chronic diseases like Crohn’s, juvenile arthritis and anorexia nervosa – or those undergoing cancer treatment – are at increased risk for bone mass deficiencies, fracture or osteoporosis as they get older, according to a new study.

“There is a huge demand for this information among clinicians because in almost any chronic condition in children affecting growth, inflammation, or involving cancer survivors, they have problem bones,’’ said Heidi Kalkwarf, Ph.D., associate professor of Community and General Pediatrics at Cincinnati Children’s, and lead author of the research report.

You have 60 days to make a difference. That's the amount of time the USDA is going to allow for comments on its amendments to add 38 inorganic ingredients to organic food.

Sound like it doesn't make sense?

Here's why it does, according to the USDA.

The 38 minor ingredients contained in the interim final rule are non-organic, agricultural ingredients that may be considered for use in an “organic” processed product. A minor ingredient cannot comprise more than 5 percent of an “organic” product.

Before an organic handling operation can consider using a non-organic, agricultural minor ingredient, the organic form of the ingredient must be first sourced and confirmed unavailable.

CTS-21166, an experimental drug to treat Alzheimer's disease, began the first phase of human clinical trials this week.

"Millions of people suffer from this devastating disease and treatment options are very limited," said Arun Ghosh, a Purdue professor who led the creation of the treatment molecule. "Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease."

Ghosh and Jordan Tang founded biopharmaceutical company Zapaq, which merged with Athenagen in 2006 to form CoMentis. CoMentis is handling the clinical trials.